Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN Advaxis.

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy company, initiated the Company’s first scientific trial site in its randomized, single blind, placebo-controlled, Phase 2 medical trial of ADXS11-001 for the treating cervical intraepithelial neoplasia online . The study is designed to measure the safety and efficacy of ADXS11-001 for the treatment of CIN grade 2/3 often called cervical dysplasia. The main investigator at the Institute for the trial is Dr. Keith Aqua, MD – a skilled medical investigator in the development of brand-new therapies for women’s wellness. His center provides two Florida sites with 84,000 energetic individuals and conducts over 2,000 Pap smears, monthly.